- Tuberculosis is a deadly infectious disease that kills many people.
- Doctors often treat tuberculosis with the antibiotic rifampicin daily.
- Some bacteria have become resistant to rifampicin in many places.
- Scientists tested rifampicin together with a second new compound.
- The second compound attacks the bacteria in a different way.
- In laboratory tests the drug pair killed resistant bacteria.
- In an animal model the two drugs worked much better.
- Researchers plan to make a stable medicine from the probe.
Difficult words
- tuberculosis — A serious disease that affects the lungs.
- infectious — Can spread from one person to another.
- antibiotic — A medicine that kills bacteria and stops infections.
- resistant — Not killed by a medicine or treatment.
- compound — A chemical substance made for research or medicine.
- laboratory — A room where scientists do tests and experiments.
Tip: hover, focus or tap highlighted words in the article to see quick definitions while you read or listen.
Discussion questions
- Have you ever taken antibiotics?
- Do you know the name of any antibiotic medicine?
- Would you like to work in a laboratory?
Related articles
Brothers build magnetic system to remove arsenic
Arsenic in Indian groundwater causes serious health problems. Two brothers from Bihar developed METAL, a chemical-free magnetic way to clean water and built the MARU unit; their startup Navmarg has treated over 300,000 litres and plans sensors and AI.
New Oral Drug Candidate for Measles and Parainfluenza
Researchers identified a clinical candidate called GHP-88310 that inhibits orthoparamyxoviruses and tested it in animal models and human airway cultures. The compound showed broad once-daily oral activity and good tolerance in animals.
Affordable twice-yearly HIV injection lenacapavir to reach 120 countries
Lenacapavir, a twice-yearly HIV prevention injection, will be licensed for 120 low- and middle-income countries at US$40 a year. Rollout is expected from 2027 with funding support, but some countries and price transparency remain concerns.
